Historical Background on the Study of Fibromyalgia Syndrome

Pain has a multidimensional nature in which three dimensions are usually differentiated: the sensory-discriminative, the emotional-affective and the cognitive-evaluative. Based on the duration, it is possible to distinguish between acute pain, when it is present for a period lower than 6 months; or chronic pain, if pain is present more than 6 months. Fibromyalgia Syndrome is a complex chronic pain disorder in which widespread and persistent musculoskeletal pain is accompanied by different symptoms such as fatigue, insomnia, morning stiffness, depression, anxiety and cognitive impairments. Fibromyalgia began to be studied from the 16th century and it received different names during its historical development. The main landmarks in the development of fibromyalgia term include -among others- when the French physician Guillaume de Baillou in 1642 provided the first description of the disease using the term “muscular rheumatism”. The British neurologist W.R. Gowers in 1904 coined the term “fibrositis” in an article on lumbago. In 1944, F. Elliot suggested that the pain experimented by fibromyalgia patients might involve the spinal cord and thalamus. In 1968, E.F. Traut stated the first near-modern description of fibromyalgia with systemic features. In 1976, the term fibromyalgia was coined by P.K. Hench as a form of non-articular rheumatism based on the absence of specific inflammatory damage. In 1977, H.A. Smythe and H. Moldofsky continued the work of P.K. Hench and proposed the first measure for evaluating fibromyalgia. Nevertheless, it was not until 1981 that the medical community accepted this disease under the term "fibrositis" or "fibromyalgia" thanks to the work of Yunus et al. The distinction between primary and secondary fibromyalgia disappeared sometime later. During the 1980s, different authors suggested other formal and ad-hoc criteria sets. In 1987, the American Medical Association accepted fibromyalgia as a real disease. Shortly thereafter and as a result of this recognition, the American College of Rheumatology (ACR) created a committee to establish the diagnostic criteria for this disorder. The first official diagnostic criteria were proposed in 1990 by the ACR. In 1994, fibromyalgia was also recognized by the International Association for the Study of Pain. During the 1990s, there was an increase in fibromyalgia research. In 2010, the ACR proposed a new version of the diagnostic criteria based exclusively on the use of the Widespread Pain Index and the Symptom Severity Scale. In addition, other two subsequent diagnostic proposals were performed. In 2011, Wolfe et al. revised and modified the 2010 ACR diagnostic criteria to facilitate its use in epidemiological or community studies, but not for self-diagnosis in the clinical context. In 2016, ACR criteria were proposed to combine the 2010 and 2011 ACR criteria into a single set to overcome the previous limitations. Definitely, fibromyalgia involves high personal, family and financial costs. Fibromyalgia also implies high economic costs for the socio-health system. Fibromyalgia notably reduces perceived functioning in physical, psychological, and social spheres, and has a negative impact on personal relationships, parenting, work, daily activities, mental health and social relationships.

Pain has been defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience, associated with actual or potential tissue damage, or described in terms of such damage”, thus including a subjective component. Pain has a multidimensional nature in which three dimensions are usually differentiated: the sensory-discriminative, the emotional-affective and the cognitive-evaluative (See Figure 1). Additionally, pain can be classified according to different aspects, such as duration, cause, or anatomical location; among others criteria. Based on the duration, it is possible to distinguish between acute pain, when it is present for a period lower than 6 months; or chronic pain, if pain is present more than 6 months. Moreover, chronic pain is a serious health problem, which has a high comorbidity with other physical and emotional diseases such as anxiety, depression, insomnia and cognitive alterations.
Fibromyalgia Syndrome is a complex chronic pain disorder that affects between 0.25 and 5% of the world population, being more frequent in women than in men, although this gender prevalence is being revised due to possible gender biases in epidemiological data. The widespread and persistent musculoskeletal pain is accompanied in fibromyalgia by different symptoms such as fatigue, insomnia, morning stiffness, depression, anxiety and cognitive impairments (i.e., deficits in attention, memory, concentration, processing speed). A high comorbidity has been observed between fibromyalgia and Rheumatoid Arthritis, Systemic Lupus Erimatosus, Ankylosing Spondylitis, and Chronic Migraine. Furthermore, fibromyalgia is also associated with emotional comorbidities such as anxiety and depression.

The origin of the term “fibromyalgia” comes from the Latin “fibro”, which means fibrous tissue; from the Greek “mio”, which means muscle and “algia”, pain. Fibromyalgia began to be studied from the 16th century and it received different names during its historical development such as muscular rheumatism, fibrositis, fibromyopathy, psychogenic rheumatism, interstitial myofibrositis, myasthenia, or neurasthenia. See some details in Figure 2.

The French physician Guillaume de Baillou in 1642 seem to be the first person who provided a description of the disease using the term “muscular rheumatism”. Baillou published this idea in his book “Liber de rheumatismo et pleuritide dorsali” and he commented that rheumatism was a type of fluid vessel disease, in which malignant humors flowed from the inside to the outside of the body, to be finally accumulated in the extremities and joints. In 1750, the British physician R. Manningham published the paper “Symptoms, Nature, Causes, and Cure of Low-grade...
Fever or Fever: Commonly Called Nervous or Hysterical Fever; Spirit Fever; Vapors, Hiccups, or Spleen and made different descriptions that might correspond to fibromyalgia.

In 1843, the German anatomist R. Froriep described the concept of “tender points” in his treatise on pathology and therapy of rheumatisms and proposed an association between rheumatism and painful points of rigid muscles.

In 1880, G.M. Beard, a neurologist from the United States, mentioned the term neurasthenia/myelasthenia to conceptualize a widespread pain (accompanied by fatigue and psychologic disturbance). Beard pointed out the daily stress of modern life as a possible cause of these symptoms.

The British neurologist W.R. Gowers in 1904 coined the term “fibrositis” in an article on lumbago, which was referred to pain on touching by the fingertips of muscles hardened by inflammation of the fibrous tissue. Gowers also pointed out the presence of spontaneous pain and hypersensitivity to mechanical pressure, together with fatigue, sleep disorders and muscular symptoms. These symptoms seem to be worsen due to cold weather and physical efforts. He proposed manipulation, counterirritation, and cocaine injections as main treatments.

In 1904, R. Stockman stated the pathological basics for the fibrous tissue inflammation theory of W.R. Gowers. Stockman proposed the existence of painful nodules, where hyperplasia was observed in inflammatory connective tissue. In subsequent publications, “fibrositis” became synonymous with a poorly defined painful disorder of rheumatic origin.

In 1909, the famous physician W. Osler, explained that muscular rheumatism involves neuralgia of the sensory nerves of the muscles. Nevertheless, North American physicians didn’t recognize fibrositis due to the uncertainty of physical signs, the inconsistent histologic changes, and the non-existence of specific laboratory tests.

In 1913, Llewellyn and Jones wrote a book, which included different medical conditions such as rheumatoid arthritis and gout, trying to catch all dimensions of fibrositis term. In addition, they divided fibrositis in articular, bursal, neural, muscular, gouty, infective, traumatic, or rheumatic.

In 1927, Albee coined the term fibromiositis. Albee applied the term “myofibrositis” or “fibromiositis” and presumably ignored their different etiology, but introduced the possibility of including different pathologies with similar clinic manifestations.

In 1936, C.H. Slocumb awoke an increasing interest in fibrositis. Slocumb stated that there was indirect evidence which confirmed the persistent integrity of the joint cavity in cases of fibrositis. While in periarticular fibrositis the disease was at the joint, not within the joint; in infectious arthritis there were fibrositis together with synovitis and other inflammatory diseases (i.e., chondritis and osteitis).

In 1944, F. Elliot suggested that the pain experimented by fibromyalgia patients might involve the spinal cord and thalamus.

In 1945, Copeman developed the first controlled study showing that fibrositic nodules had a similar frequency in patients with fibromyalgia and in control subjects. In this sense, the Stockman theory was refuted because biopsies performed on muscle tissues did not provide any evidence of inflammation. As a result, some authors explain that these initial uses of the term fibrositis in 1904 by Stockman, cannot be considered synonymous with fibromyalgia due to its association with inflammatory responses.

In 1947, E.W. Boland based on the absence of physical findings corresponding to the symptomatology, modified the concept and reintroduced the term “psychogenic rheumatism”, defined as musculoskeletal expression of functional disorders, stress states, or psychoneurosis.

Some years later, a Boston physician called W. Graham (1953) used the term “fibrositis” to indicate a pain syndrome in the absence of any specific organic disease. In opinion of this author, the etiology may be infective, traumatic/occupational, or due to weather factors and psychologic disturbance. This concept was accepted in the 1920s by European physicians. The term fibrositis, when assumed this meaning, might be considered as synonymous
In 1959, E.F. Rossenberg outlined a classification for "fibrositis". Later, in 1989, C. Vitali stated the need for a classification of "primary fibromyalgia syndrome" or fibrositis.

In 1968, E.F. Traut conceptualized "muscular fibrositis" or "non-articular rheumatism" as a syndrome defined by pain and stiffness present in trigger areas, in which the soft tissues of the neck, shoulder, elbow, carpal tunnel, palms (Dupuytren’s contracture) and lower back area were included. To his mind, a cold or damp environment could be also implicated in the aggravation of this illness, which is similar to the Gower’s idea in 1904. Traut also considered that the syndrome was practically limited to women, usually in the climacteric years. This idea has been rejected with the subsequent evidence of fibromyalgia in women of different age, in men, and in pediatric population. Additionally, in the case of symptoms of muscular fibrositis in men, Traut explained they were more related to some recent, unexpected, unusual or persistent fatiguing effort. It is considered that Traut stated the first near-modern description of fibromyalgia with systemic features. He also contributed to the study of fibromyalgia emphasizing the role of mind-body interactions in the pathogenesis of the disease.

In 1976, the term fibromyalgia was coined by P.K. Hench as a form of non-articular rheumatism based on the absence of specific inflammatory damage.

In 1977, H.A. Smythe and H. Moldofsky continued the work of P.K. Hench and proposed the first measure for evaluating fibromyalgia in their work entitled “Two contributions to the understanding of the fibrositis syndrome”. This work influenced many fibromyalgia researchers in the 1970s and 1980s. It is considered that Smythe is the grandfather of modern fibromyalgia. It seems that he was the first to conceptualize fibromyalgia exclusively as a generalized pain syndrome, accompanied by fatigue, nonrestorative sleep, morning stiffness, emotional distress, and multiple tender points. They proposed diagnostic criteria based on the core symptoms previously mentioned. Smythe also pointed out the presence of aggravating and relieving factors. At this regard, several authors have confirmed the existence of a series of factors that seem to modulate the symptoms of fibromyalgia. Among the factors that aggravate the symptoms are cold, stress, professional or domestic work overload, environmental noise, obesity and tobacco.

Furthermore, thanks to Smythe and Moldofsky, the role of sleep was properly recognized. Smythe offered a description of a real patient experience and provided sleep electroencephalogram (EEG) findings of absent stage-4 and near-absent stage-3 sleep, based on the unpublished work of his colleague Moldofsky. These authors also hypothesized serotonin deficiency as a cause for such sleep anomalies in fibromyalgia. Moreover, they stated the possible role of distress in the beginning of fibromyalgia symptoms. They specifically suggested mechanical stress in the deep structures of the cervical and lumbosacral spine region as a factor for sustained reflex hyperalgesia.

Nevertheless, it was not until 1981 that the medical community accepted this disease under the term "fibrositis" or "fibromyalgia". This medical recognition was related to the work of Yunus et al. that proposed the first formal set of criteria to diagnose primary fibromyalgia. Yunus conceptualized fibrositis or fibromyalgia as a form of nonarticular rheumatism in which predominant symptoms were chronic aches, pains, and stiffness in multiple areas of the musculoskeletal system, together with increased tenderness at specific tender or trigger points.

Yunus also introduced the term secondary fibrositis for cases wherein a secondary condition (e.g., inflammation) were provoking the syndrome. The distinction between primary and secondary fibromyalgia disappeared sometime later. The criteria of Yunus et al. represented an important point in the study of fibromyalgia because it was the first time in which symptoms played a more central role in fibromyalgia diagnosis, which notably contributed to the understanding and treatment of this illness. In addition, Yunus had the credit for carrying out the first controlled study about the clinical characteristics of fibromyalgia, following a formal protocol and including 50 fibromyalgia patients and 50 matched healthy controls.

During the 1980s, different authors suggested other formal and ad-hoc criteria sets. In 1985, Yunus et al. performed the first description of juvenile fibromyalgia in a controlled study. In 1987, D.L. Goldenberg published a set of
diagnostic criteria for fibromyalgia, distinguishing between mandatory and minor diagnostic criteria.\textsuperscript{51} In 1988, Vaeroy et al.\textsuperscript{52} developed the first report of elevated substance P in cerebrospinal fluid of patients with fibromyalgia, being confirmed these results by Rusell in 1994.\textsuperscript{53} In 1989, J.I. Hudson proposed overlaps between fibromyalgia and related conditions as well as several psychiatric illnesses.\textsuperscript{54} However, sometime later these syndromes were proposed to be more connected to central sensitization rather than by affective mechanisms.\textsuperscript{55,56}

In 1987, the American Medical Association accepted fibromyalgia as a real disease. Shortly thereafter and as a result of this recognition, the American College of Rheumatology (ACR) created a committee to establish the diagnostic criteria for this disorder.\textsuperscript{57}

The first official diagnostic criteria were proposed in 1990 by the ACR and it was definitely decided to use the term fibromyalgia instead of fibrositis. In 1992, the World Health Organization (WHO) recognized fibromyalgia as a disease and it was classified within non-articular rheumatisms under code M.79.7 of the International Classification of Diseases (ICD).\textsuperscript{57} And since 1992, every May 12\textsuperscript{th}, World Fibromyalgia and Chronic Fatigue Syndrome Day is celebrated. In 1994, fibromyalgia was also recognized by the International Association for the Study of Pain (IASP) and classified with the code x33 x8a.\textsuperscript{57}

During the 1990s, there was an increase in fibromyalgia research. Some of the most relevant researches were the first demonstration of hypothalamic-pituitary-adrenal axis abnormalities in a well-designed study which showed exaggerated ACTH (adrenocorticotropic hormone) release with relative hypo-responsiveness,\textsuperscript{58} the first United States population study showing 2% prevalence of fibromyalgia,\textsuperscript{59} the first study of brain imaging by SPECT (Single Photon Emission Computed Tomography) showing decreased cerebral blood flow in thalami and caudate nucleus,\textsuperscript{60} etc. Moreover, in 2000, Yunus et al.\textsuperscript{65} performed an important review of evidence for central sensitization in fibromyalgia and other related syndromes in which the term central sensitization syndromes was coined. One year later R. Staud performed a well-designed study showing temporal summation of pain in fibromyalgia.\textsuperscript{66} Nowadays, the presence of central sensitization to pain and deficits in endogenous pain inhibitory mechanisms in fibromyalgia is one of the most well supported hypotheses regarding its pathophysiology.\textsuperscript{61,62}

In 2010, the ACR proposed a new version of the diagnostic criteria based exclusively on the use of two scales: the Widespread Pain Index (WPI) and the Symptom Severity (SS) Scale. In addition, other two subsequent diagnostic proposals were performed.\textsuperscript{16} In 2011, Wolfe et al. revised and modified the 2010 ACR diagnostic criteria. These modifications were made to facilitate its use in epidemiological or community studies, but not for self-diagnosis in the clinical context.\textsuperscript{63} In 2016, ACR criteria were proposed to combine the 2010 and 2011 ACR criteria into a single set to overcome the previous limitations.\textsuperscript{64}

Definitely, fibromyalgia involves high personal, family and financial costs. Fibromyalgia provokes disability and dependence on the family to perform daily activities, which at the same time causes stress and discomfort in people who suffer from fibromyalgia and their relatives; as well as feelings of guilt and frustration in the patients which worsen their medical condition. In addition, many fibromyalgia patients are unable to go to work and this make their own and the family's economic situation worse.\textsuperscript{65}

Moreover, fibromyalgia patients showed low Health Related Quality of Life levels, regardless of the presence of comorbidities.\textsuperscript{66,67,68,69} Fibromyalgia notably reduces perceived functioning in physical, psychological, and social spheres, and has a negative impact on personal relationships, parenting, work, daily activities, mental health and social relationships.\textsuperscript{70,71,72}

Regarding socio-economic costs, fibromyalgia implies high economic costs for the socio-health system, because of these patients go more to the medical office (both to general medicine and to different medical specialties) and need more prescriptions and medical tests (especially neuroimaging and laboratory tests) than the rest of the population.\textsuperscript{65} It is estimated that before obtaining the correct diagnosis, fibromyalgia patients have twice of visits to the general practitioner and twice of prescriptions compared to other disorders.\textsuperscript{69}
References

1. Pain IASP Taxonomy . International Association for the Study of Pain-IASP. Retrieved 2020-6-13

2. M. M. Veehof; Maarten-Jan Oskam; Karlein M.G. Schreurs; Ernst T. Bohmniej; Acceptance-based interventions for the treatment of chronic pain: A systematic review and meta-analysis. Pain 2011, 152, 533-542, 10.1016/j.pain.2010.11.002.

3. Ronald Melzack; Pain and the Neuromatrix in the Brain. Journal of Dental Education 2001, 65, 1378-1382, 10.1002/.0022-0337.2001.65.12.tb03497.x.

4. Frederick Wolfe; Hugh A. Smythe; Muhammad B. Yunus; Robert Bennett; Claire Bombardier; N L. Goldenberg; Peter Tugwell; Stephen Campbell; Micha Abeles; Patricia Clark; et al. Adel G. FamStephen J. FarberJustus J. Fiechteiner C. Michael FranklinRobert A. GatterDaniel HamatyJames LessardAlan S. LichtbrounAlfonse T. Masiglenn A. McCain W. John Reynolds Thomas J. Romanol. Jon Russell Robert P. Sheon The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Care & Research 1990, 33, 160-172, 10.1002/art.1780330203.

5. Sachin Srinivasan; Eamon Maloney; Brynn Wright; Michael Kennedy; K. James Kallai; Johannes J. Rasker; Winfried Häuser; Frederick Wolfe; The Problematic Nature of Fibromyalgia Diagnosis in the Community.. ACR Open Rheumatology 2019, 1, 43-51, 10.1002/acr2.1006.

6. Frederick Wolfe; Brian Walitt; Serge Perrot; Johannes J. Rasker; Winfried Häuser; Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias. PLOS ONE 2018, 13, e0203755.

7. Jennifer M. Glass; Denise C. Park; Meredith Minear; Leslie J. Crofford; Memory beliefs and function in fibromyalgia patients. Journal of Psychosomatic Research 2005, 58, 263-269, 10.1016/j.jpsychores.2004.09.004.

8. John McBeth; Matthew R. Mulvey; Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. Nature Reviews Rheumatology 2012, 8, 108-116, 10.1038/nrrheum.2011.216.

9. Ricardo Campos; Maria Isabel Rodríguez Vázquez; Health-related quality of life in women with fibromyalgia: clinical and psychological factors associated. Clinical Rheumatology 2011, 31, 347-355, 10.1007/s10067-011-1870-7.

10. Carmen M. Galvaz-Sánchez; Gustavo A. Reyes Del Paso; Stefan Duscheck; Cognitive Impairments in Fibromyalgia Syndrome: Associations With Positive and Negative Affect, Alexithymia, Pain Catastrophizing and Self-Esteem. Frontiers in Psychology 2018, 8, 1-14, 10.3389/fpsyg.2018.00377.

11. Carmen M. Galvaz-Sánchez; Cristina Muñoz; Casandra I. Montoro; María José Fernández-Serrano; Stefan Duscheck; Gustavo A. Reyes Del Paso; Cognitive deficits in fibromyalgia syndrome are associated with pain responses to low intensity pressure stimulation. PLOS ONE 2018, 13, e0201488, 10.1371/journal.pone.0201488.

12. Fabienne Coury; Arnaud Rossat; Alexandre Tebib; Marie-Claude Letroublon; Anne Gagnard; Bruno Fantino; Jacques G. Tebib; Rheumatoid Arthritis and Fibromyalgia: A Frequent Unrelated Association Complicating Disease Management. The Journal of Rheumatology 2009, 36, 58-62, 10.3899/jrheum.080366.

13. Frederick Wolfe; Michelle Petri; Graciela S. Alarcón; John Goldman; Eliza F. Chakravarty; Robert S. Katz; Elizabeth W. Karlson; Kaleb Russell; John B. Winfield; Muhammad B. Yunus; et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Comorbidity in Primary Headaches. Cephalalgia 2009, 29, 453-464, 10.1111/j.1468-2982.2008.01754.x.

14. Frederic Wolfe; Daniel J. Clauw; Mary-Ann Fitzcharles; N L. Goldenberg; Robert S. Katz; Philip Mease; Anthony S. Russell; I. Jon Russell; John B. Winfield; Muhammad B. Yunus; et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care & Research 2010, 62, 600-610, 10.1002/acr.20140.

15. George Beard; Neurasthenia, or Nervous Exhaustion. Archives of Physical Medicine and Rehabilitation 1904, 21, 117-121, 10.1136/ard.6.4.195.

16. Valderilio Feijó Azevedo; Eduardo Dos Santos Paiva; Lúcio Ricardo Hiurko Felippe; Ranieri Amorim Moreira; Concomitância de fibromialgia em pacientes com espondilite anquilosante. Revista Brasileira de Reumatologia 2010, 50, 646-650, 10.1590/s0482-50042010000600005.

17. Marina De Tommaso; M Sardaro; C Serpino; F Costantini; F Vecchio; M Pia Prudenzano; P Lambertii; P Livrea; Fibromyalgia Comorbidity in Primary Headaches. Cephalalgia 2009, 29, 453-464, 10.1111/j.1468-2982.2008.01754.x.

18. Michael Campbell; Patricia Addis; Elisa F. Chakraverty; Robert S. Katz; Elizabeth W. Karlson; Kaleb Russell; John B. Winfield; Muhammad B. Yunus; et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care & Research 2010, 62, 600-610, 10.1002/acr.20140.

19. Murray, G; An Address ON MYOFIBROSITIS AS A SIMULATOR OF OTHER MALADIES.. The Lancet 1929, 213, 113-116, 10.1016/s0140-6736(00)82431-9.

20. Gowers, W.R; The development of the concept of fibrositis.. Br Med J 1904, 1, 117-121.

21. Robert M. Bennett; Fibrositis: Misnomer for a Common Rheumatic Disorder. Western Journal of Medicine 1981, 134, 405-413.

22. E A Awad; Intestinal myofibroblasts: hypothesis of the mechanism.. Archives of Physical Medicine and Rehabilitation 1973, 54, 449–453.

23. Baillou, G. Liber de Rheumatismo et pleuritide dorsali; Thevart MJ: Thevart MJ: Paris, France, 1642; pp. 25.

24. R. Manningham. Symptoms, Nature, Causes, and Cure of Low-grade Fever or Fever: Commonly Called Nervous or Hysterical Fever; Spirit Fever; Vapors, Hiccups, or Spleen; J. Robinson, Eds.; British Library; London: British Library, 1750; pp. 138.

25. Quiros Álvarez, Oscar J; Rodríguez, Liliana; Lezama, Ernesto; Quiros C, Jelsyka; Quiros C, Luzmarina; Fibromialgia y Ortodoncia. Actitud del Ortodoncista ante la enfermedad invisible. Acta odontol. venez 2002, 40 (2), 144-151.

26. Froire R. Ein beitrag zur pathologie und therapie des rheumatismus; Weimar: Weimar, Germany, 1843; pp. 292.
Fibromyalgia; Chronic Pain; Fibrositis

Keywords

Fibromyalgia, Chronic Pain, Fibrositis

Retrieved from https://encyclopedia.pub/1672